120 cases of STEMI who presented to the Medicine casualty who were treated with thrombolysis
for during the period from January 1991 to January 2005 were followed up and the longterm outcome in each of the patients were studied.
Currently options of treatment include surgical treatment, thrombolysis
, anticoagulation and percutaneous aspiration.
Although intra-arterial thrombolysis
is of higher recanalization rate, the benefit achieved might be counteracted by the delay of time.
In this report, we describe the first published use of ultrasound-assisted thrombolysis
for TIPS occlusion.
4,5 Numerous studies had confirmed that early intravenous thrombolysis
was an effective method to treat acute ischemic stroke (AIS), and the earlier the thrombolytic therapy, the greater the likely benefits for the patients, and the risk of bleeding transformation would also be reduced.
reduces the mortality in high-risk patients (16,17) and maybe considered for intermediate-high risk patients (14) ; its principal benefit is based on the quick recovery of the pulmonary blood flow, but it is associated with major bleeding complications in up to 20% of the cases, and with intracranial hemorrhage with an incidence of 0.
is clearly beneficial in high-risk patients, with haemodynamic instability, but in intermediate and low-risk patients, haemodynamically stable, the beneficial effects are missing and the haemorrhagic risks are high.
The third section included information about presence of risk factors: hypertension, coronary artery disease, diabetes, atrial fibrillation, prior stroke or TIA, smoking, and hyperlipidemia, as documented in the medical record and assessment of knowledge about these risk factors and knowledge about thrombolysis
Nguyen and colleagues (5) reported an interest in intra-arterial thrombolysis
early in acute ischemic strokes and considered a three hour period as a viable time frame to interfere.
At 90 days after treatment, 59 patients (60%) among those treated with thrombolysis
plus embolectomy had a modified Rankin Scale score of 0-2, compared with 33 patients (36%) among those treated only with thrombolysis
(in this trial intravenous treatment with tissue plasminogen activator), a highly significant difference for the study's primary endpoint.
is limited by the risk of hemorrhagic complications, especially with long acting fibrinolytic agents, longer infusions and with an underlying bleeding predisposition.
Objective: To determine the reporting time of ischemic stroke patients within the time window for thrombolysis
at Military Hospital (MH) Rawalpindi.